Medicaid Drug Rebate Program Update – Impact of Regulatory Changes
A lot of activity has recently taken place in the regulatory world that impacts Medicaid processing, including CMS Release #91 with changes to payments for terminated products, the AMP Final Rule and a new base date AMP, and upcoming requirements to calculate inflation for non-innovator drugs. What does this mean to your MDRP processes? How is Revitas addressing these updates? This session will review the impacts from the latest regulatory changes, and it will address the impact of future developments.